Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy

Glueck, Charles J.; Goldenberg, Naila; Wang, P.; Loftspring, M.; Sherman, A.

doi:10.1093/humrep/deh109

Cited by 159 publications

(119 citation statements)

References 45 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Of the 25 trials included for this review, there were four randomised controlled trials (RCTs) [10][11][12][13], one clinical trial [14], four retrospective cohort studies [15][16][17][18], and sixteen prospective cohort studies [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34]. These studies were conducted globally with a large number originating from USA.…”

Section: Resultsmentioning

confidence: 99%

Use of metformin during pregnancy for women with polycystic ovary syndrome

Fan¹

2013

OJOG

View full text Add to dashboard Cite

Objective: The purpose of this article is to review the literature assessing foetal and maternal pregnancy outcomes in women with PCOS who used metformin during pregnancy. Study Design: A literature search was conducted using MEDLINE, with analysis of 25 studies that recorded neonatal and maternal outcomes in women who used metformin during pregnancy. The outcomes assessed in this review include congenital deformities, miscarriages, preterm labour, gestational diabetes (GDM) and pregnancy induced hypertension (PIH). Results: We found that the use of metformin throughout pregnancy correlated with decreased rates of preterm labour, GDM and PIH. Conflicting evidence exists over whether metformin use during pregnancy reduced miscarriage rates. The use of metformin during pregnancy did not increase teratogenicity risks. Conclusion: The use of metformin throughout pregnancy is associated with decreased rates of preterm labour, GDM, and PIH. However, more randomised controls involving larger numbers of participants are required for more definitive results.

show abstract

Section: Resultsmentioning

confidence: 99%

Use of metformin during pregnancy for women with polycystic ovary syndrome

Fan¹

2013

OJOG

View full text Add to dashboard Cite

show abstract

“…Testosterone levels fell 30% from baseline at their last preconception visit. 20 The main limitation in this study is that there was an average weight loss of 11.8 kg before conception. The decrease in GDM may not have been the result of continuation of metformin, but rather may have resulted from one of the cornerstones of therapy for women with PCOS who are planning to become pregnant: preconception weight loss.…”

Section: Gdmmentioning

confidence: 89%

Polycystic Ovary Syndrome and Pregnancy: Is Metformin the Magic Bullet?

Zisser¹

2007

Diabetes Spectrum

View full text Add to dashboard Cite

In Brief This article reviews the literature regarding the effects of metformin therapy in pregnant women with polycystic ovary syndrome on weight loss,fertility, early pregnancy loss, malformations, gestational diabetes mellitus,perinatal mortality, placental clearance, lactation, and early childhood development. The pharmacology of metformin is also presented. Preliminary data suggest that metformin for this population may be both safe and effective. Large blinded, randomized clinical trials are underway to confirm the preliminary safety data.

show abstract

“…However, to our knowledge, few studied reported quantitative information on possible amelioration of beta-cell function. [8][9][10] The study by Hebert et al [8] included 40 women with GDM, 40 healthy pregnant and 26 non-pregnant women with type 2 diabetes. All women with GDM, and the majority of women with type 2 diabetes, were treated with glyburide twice daily.…”

Section: Evidence Of the Effects Of Treatment On Beta-cell Functionmentioning

confidence: 99%

“…In the study by Glueck et al, [9] a group of 39 women with polycystic ovary syndrome, treated with metformin, were studied before and during pregnancy. Some of them developed GDM, but due to the limited number of cases, results were not presented separately for women with and without diabetes.…”

Section: Evidence Of the Effects Of Treatment On Beta-cell Functionmentioning

confidence: 99%

“…This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties. [8] 40 women Glyburide Model-based indices (beta-cell responsivity, disposition index), based on mixed meal test Glueck et al [9] 3 of 39 polycystic ovary syndrome women Metformin Empirical index (HOMA beta-cell)…”

Section: Declaration Of Interestmentioning

confidence: 99%

See 1 more Smart Citation

Effects of antidiabetic agents on pancreatic beta-cell function in gestational diabetes: is there enough evidence?

Tura

Göbl

Pacini

2016

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is typically characterized by the presence of insulin resistance. However, recent studies showed that both insulin resistance and pancreatic beta-cell function impairment may contribute to the development of type 2 diabetes in women with history of GDM. In fact, beta-cell function decline was found as significant predictor of later disease in former GDM women progressing towards type 2 diabetes. Despite the evidence of the relevance of beta-cell function quantification in GDM, a low number of studies focused on the effects of GDM treatments on beta-cell function. We briefly present the evidence of the effects on beta-cell function of pharmacological agents, as well as nutrition supplements or medical nutrition therapy, used in the management of GDM. We found that few studies reported information on beta-cell function effects in GDM, despite some agents, such as glyburide, are well known insulin secretagogues. Therefore, further studies should be carried out to clearly assess the effects on beta-cell function of the treatments in GDM women.

show abstract

Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy

Abstract: By reducing preconception weight, insulin, IR, insulin secretion and testosterone, and by maintaining these insulin-sensitizing effects throughout pregnancy, MET-diet reduces the likelihood of developing GD, and prevents androgen excess for the fetus.

Cited by 159 publications

References 45 publications

Use of metformin during pregnancy for women with polycystic ovary syndrome

Use of metformin during pregnancy for women with polycystic ovary syndrome

Polycystic Ovary Syndrome and Pregnancy: Is Metformin the Magic Bullet?

Effects of antidiabetic agents on pancreatic beta-cell function in gestational diabetes: is there enough evidence?

Contact Info

Product

Resources

About